Clinical trials: Lymphoproliferative Disorder
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00274924
- Testing
- filgrastim, rituximab, carboplatin
- Where
- 104 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoma
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
- Trial name
- NCT03786926
- Testing
- HMPL-689
- Where
- 27 sites in United States, Finland and 4 more
- Volunteers
- 53 people
- Sponsor
- Hutchmed
Multiple Myeloma
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin…
- Trial name
- NCT00750815
- Testing
- Cyclophosphamide, Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone.
- Trial name
- NCT03290950
- Testing
- daratumumab, carfilzomib, lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Follicular Lymphoma, Lymphoma, Follicular
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
This study will treat follicular lymphoma patients who have not received previous treatment with R-CVP. Half of the patients will receive Zevalin after R-CVP and the other half will receive only R-CVP.
- Trial name
- NCT00384111
- Testing
- Zevalin Therapeutic Regimen, R-CVP
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether ATIR is safe and effective in reducing transplant-related mortality and improving overall survival, when infused in patients with a hematologic malignancy following a T-cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01794299
- Testing
- ATIR
- Where
- 8 sites in Belgium, Canada and 2 more
- Volunteers
- 31 people
- Sponsor
- Kiadis Pharma
Multiple Myeloma and Plasma Cell Neoplasm
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body.
- Trial name
- NCT00566098
- Testing
- MILs, Melphalan, PCV13
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma, Mantle- Cell
Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
This study was to evaluate the safety and efficacy of a daily, oral dose of 10 mg RAD001 in participants with Mantle Cell Lymphoma who were refractory or intolerant to Velcade® therapy and who had received at least one prior…
- Trial name
- PILLAR-1 (NCT00702052)
- Testing
- Everolimus
- Where
- 31 sites in United States
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders
Stem Cell Transplant for Immunologic or Histiocytic Disorders
This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU), anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell transplant, and a post transplant regimen of…
- Conditions
- Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome
- Trial name
- NCT00176865
- Testing
- Stem Cell Transplant, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma
The purpose of this study is to determine wether activated and expanded autologous Natural Killer cells (NKAEs) are effective in the treatment of patients with multiple myeloma on second or later relapse.
- Trial name
- NK-VS-MM (NCT02481934)
- Testing
- NKAE cells infusion, Lenalidomide, Bortezomib
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Joaquín Martínez López, MD, PhD
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT01075321
- Testing
- everolimus, lenalidomide, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Mayo Clinic
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
The standard approach to managing chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) is to wait until you have symptoms before treatment is given.
- Conditions
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT03207555
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Double Cord Versus Haploidentical (BMT CTN 1101)
Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar tissue type can be used for HCT.
- Conditions
- Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma, Follicular Lymphoma
- Trial name
- NCT01597778
- Testing
- Haploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant
- Where
- 39 sites in United States
- Volunteers
- 368 people
- Sponsor
- Medical College of Wisconsin
Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.
- Conditions
- Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
- Trial name
- NCT04788043
- Testing
- Magrolimab, Pembrolizumab, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Ranjana Advani
Diffuse Large B-Cell Lymphoma
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
This study is being done to evaluate if ME-401 can improve the treatment of patients with diffuse large b-celllymphoma (DLBCL). Many patients with DLBCL that are treated with the standard of care (R-CHOP) are cured.
- Trial name
- NCT04517435
- Testing
- ME-401, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Deepa Jagadeesh
Chronic Lymphocytic Leukemia
Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy
This is a phase I - II multicenter, non-comparative, open label study in patients with previously treated CLL aimed at defining the MTD of Lenalidomide given in combination with Fludarabine, Cyclophosphamide and at evaluating the…
- Trial name
- LLC0606 (NCT00727415)
- Testing
- Cyclophosphamide, Fludarabine phosphate, Lenalidomide
- Where
- 23 sites in Italy
- Volunteers
- 42 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: efprezimod alfa vs placebo with the standard GVHD prophylaxis of tacrolimus / methotrexate.
- Conditions
- Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- CATHY (NCT04095858)
- Testing
- Efprezimod alfa, Methotrexate, Tacrolimus
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Diffuse Large B-cell Lymphoma (DLBCL)
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.
- Trial name
- JULIET (NCT02445248)
- Testing
- Tisagenlecleucel, Lymphodepleting chemotherapy
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Leukemia
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
This research study is evaluating a new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
- Trial name
- iFCR (NCT02251548)
- Testing
- Ibrutinib, Fludarabine, Cyclophosphamide
- Where
- 9 sites in United States
- Volunteers
- 85 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005914
- Testing
- cyclophosphamide, cytarabine, dexamethasone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.